LY-586713

{{Infobox drug | IUPAC_name = (2S)-2-[[4-(4-fluorophenyl)-6-isopropyl-2-(methylsulfonyl)pyrimidin-5-yl]oxy]-3-phenylpropanoic acid | image = | width = | alt = | legal_status = | routes_of_administration = | bioavailability = | protein_bound = | metabolism = | elimination_half-life = | excretion = | CAS_number = | ATC_prefix = | ATC_suffix = | PubChem = | DrugBank = | ChemSpiderID = | UNII = | KEGG = | ChEBI = | ChEMBL = | synonyms = }}

LY-586713 is a chemical compound that has been studied for its potential therapeutic effects, particularly in the context of cardiovascular disease and metabolic disorders. It is classified as a pharmaceutical drug under investigation, and its development has been primarily driven by its action as a peroxisome proliferator-activated receptor (PPAR) agonist.

Mechanism of Action

LY-586713 functions as a selective agonist for the PPAR family of nuclear receptors, specifically targeting the PPAR-alpha and PPAR-gamma subtypes. These receptors play a crucial role in the regulation of lipid metabolism, glucose homeostasis, and inflammatory responses. By activating these receptors, LY-586713 can modulate the expression of genes involved in these metabolic pathways, potentially leading to improved lipid profiles and enhanced insulin sensitivity.

Pharmacokinetics

The pharmacokinetic profile of LY-586713 includes its absorption, distribution, metabolism, and excretion (ADME) characteristics. While specific data on its bioavailability and half-life are limited, studies suggest that it is metabolized primarily in the liver and excreted via the renal pathway. The compound's ability to bind to plasma proteins and its metabolic stability are critical factors influencing its therapeutic efficacy and safety.

Clinical Research

Clinical trials involving LY-586713 have explored its efficacy in treating conditions such as type 2 diabetes mellitus and dyslipidemia. Preliminary results indicate that LY-586713 may improve glycemic control and reduce triglyceride levels in patients. However, further studies are necessary to fully understand its long-term effects and potential side effects.

Potential Side Effects

As with many PPAR agonists, LY-586713 may be associated with certain adverse effects. These can include weight gain, edema, and potential impacts on liver function. Monitoring of liver enzymes and careful dose management are recommended during its use in clinical settings.

Regulatory Status

As of the latest updates, LY-586713 remains an investigational drug and has not yet received approval from major regulatory bodies such as the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA). Ongoing research and clinical trials will determine its future availability and therapeutic applications.

Also see

• Peroxisome proliferator-activated receptor
• Type 2 diabetes mellitus
• Dyslipidemia
• Pharmacokinetics